In 2004, the Food and Drug Administration (FDA) approved the determination of cystatin C as a marker of alternative GFR calculation for early diagnosis of renal glomerular dysfunction, determination of CKD stage, and prognosis of disease progression. This evidence concerns the gene CST3 and chronic kidney disease.